[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Natera Inc (NTRA)

Natera Inc (NTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,808,052
  • Shares Outstanding, K 143,215
  • Annual Sales, $ 2,306 M
  • Annual Income, $ -208,160 K
  • EBIT $ -317 M
  • EBITDA $ -273 M
  • 60-Month Beta 1.56
  • Price/Sales 13.16
  • Price/Cash Flow N/A
  • Price/Book 16.99

Options Overview Details

View History
  • Implied Volatility 54.90% (+3.85%)
  • Historical Volatility 59.19%
  • IV Percentile 74%
  • IV Rank 50.24%
  • IV High 76.67% on 04/23/26
  • IV Low 32.92% on 06/16/25
  • Expected Move (DTE 12) 15.60 (7.24%)
  • Put/Call Vol Ratio 0.86
  • Today's Volume 578
  • Volume Avg (30-Day) 1,440
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 28,939
  • Open Int (30-Day) 26,054
  • Expected Range 199.71 to 230.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 4
  • High Estimate $-0.36
  • Low Estimate $-0.59
  • Prior Year $-0.74
  • Growth Rate Est. (year over year) +36.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
184.81 +16.50%
on 05/15/26
227.90 -5.52%
on 06/04/26
+8.54 (+4.13%)
since 05/05/26
3-Month
181.00 +18.96%
on 03/27/26
227.90 -5.52%
on 06/04/26
+18.17 (+9.22%)
since 03/05/26
52-Week
131.81 +63.35%
on 08/01/25
256.36 -16.01%
on 01/07/26
+49.80 (+30.09%)
since 06/05/25

Most Recent Stories

More News
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class...

NTRA : 215.31 (-3.06%)
CYDY : 0.2924 (-0.85%)
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company’s board of directors....

NTRA : 215.31 (-3.06%)
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Signatera™ to evaluate molecular response to investigational dendritic cell therapy as part of Diakonos’ Phase I/II trial

NTRA : 215.31 (-3.06%)
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

Signatera ™ will be used to identify patients who may be able to delay or defer adjuvant CDK4/6 inhibitor therapy in intermediate-risk HR+/HER2- breast cancer ...

NTRA : 215.31 (-3.06%)
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

Study provides prospective, clinically-validated performance data at challenging low fetal fraction levels, raising industry standard Reduces no-call rate to 0.5%, enabling...

NTRA : 215.31 (-3.06%)
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

Overall program, including 3 oral presentations, delivers unmatched evidence across the MRD landscape

NTRA : 215.31 (-3.06%)
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World

Company to open second facility and new lab space to accommodate rapid growth

NTRA : 215.31 (-3.06%)
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled

Milestone follows prestigious oral plenary presentation of EXPAND data at SMFM Annual Meeting

NTRA : 215.31 (-3.06%)
1 Mid-Cap Stock with Exciting Potential and 2 That Underwhelm

1 Mid-Cap Stock with Exciting Potential and 2 That Underwhelm

NTRA : 215.31 (-3.06%)
GGG : 74.34 (+0.04%)
J : 122.55 (-0.83%)
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera’s Treatment on MRD (TOMR) approach...

NTRA : 215.31 (-3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

3rd Resistance Point 227.34
2nd Resistance Point 224.74
1st Resistance Point 220.02
Last Price 215.31
1st Support Level 212.71
2nd Support Level 210.11
3rd Support Level 205.39

See More

52-Week High 256.36
Last Price 215.31
Fibonacci 61.8% 208.78
Fibonacci 50% 194.09
Fibonacci 38.2% 179.39
52-Week Low 131.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.